

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**愛帝宮母嬰健康股份有限公司**  
**AIDIGONG MATERNAL & CHILD HEALTH LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 286)**

## **INSIDE INFORMATION**

### **(1) DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT AND DELAY IN DESPATCH OF ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024; (2) FURTHER INFORMATION ON THE RESUMPTION GUIDANCE; AND (3) CONTINUED SUSPENSION OF TRADING**

This announcement is made by Aidigong Maternal & Child Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to the announcements of the Company dated 19 September 2024, 17 January 2025, 5 March 2025 and 13 March 2025 (the “**Announcements**”) in relation to, among others, (i) possible delay in the publication of annual results and (ii) the Resumption Guidance. Unless otherwise defined or the context otherwise requires, capitalised terms in this announcement shall have the same meanings as defined in the Announcements.

## **DELAY IN PUBLICATION OF ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024 (“2024 ANNUAL RESULTS”)**

Pursuant to Rule 13.49(1) of the Listing Rules, the Company is required to publish an announcement in relation to its preliminary results in respect of the financial year ended 31 December 2024 not later than three months after the end of the financial year of the Company, i.e. on or before 31 March 2025. Under Rule 13.49(2) of the Listing Rules, the preliminary announcement in relation to the 2024 Annual Results shall be based on the Company’s financial statements for the year ended 31 December 2024 which shall have been agreed with the auditor of the Company (the “**Auditor**”).

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) that, based on the Company’s communication with the Auditor, the Company will not be able to publish the 2024 Annual Results on or before 31 March 2025 in accordance with Rules 13.49(1) and (2) of the Listing Rules as the issues outlined in the announcement of the Company dated 17 January 2025 have not been resolved, which have created considerable challenges for the Auditor to complete the annual audit of the Company’s financial statements and its consolidated results for the year ended 31 December 2024.

Rule 13.49(3) of the Listing Rules provides that where an issuer is unable to issue its preliminary results in accordance with Rules 13.49(1) and 13.49(2) of the Listing Rules, it must announce its results based on the financial results which have yet to be agreed with the Auditor (so far as the information is available). The Board, after due and careful consideration, is of the view that it would not be appropriate for the Company to publish the unaudited management accounts of the Group for the year ended 31 December 2024 at this stage as such management accounts may not accurately reflect the financial performance and position of the Group.

The Company will continue to communicate with the Auditor to complete the relevant reporting and auditing procedures as soon as possible. The expected date of the publication of the 2024 Annual Results will need to be further agreed with the Auditor and a separate announcement will be made by the Company as and when appropriate.

## **DELAY IN DESPATCH OF ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024 (“2024 ANNUAL REPORT”)**

Pursuant to Rule 13.46(2) of the Listing Rules, the Company is required to despatch its 2024 Annual Report to the Shareholders no later than four months after the end of the financial year, i.e. on or before 30 April 2025. Due to the delay in the publication of the 2024 Annual Results, it is expected that there may be a possible delay in the despatch of the 2024 Annual Report. The possible delay in despatch of the 2024 Annual Report, if materialised, will constitute a non-compliance with Rule 13.46(2) of the Listing Rules.

## **FURTHER INFORMATION ON THE RESUMPTION GUIDANCE**

With respect to the Resumption Guidance, the Company would like to specify that, in addition to those already disclosed in the announcement of the Company dated 13 March 2025, it shall (i) conduct an independent forensic investigation into (a) the Matters; (b) the suspected forgery of chop/document; and (c) the alleged falsification with respect to the Change of Legal Representative, (ii) assess the impact on the Company’s business operation and financial position, (iii) announce the findings and (iv) take appropriate remedial actions.

## **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended since 9:54 a.m. on 21 February 2025 and will remain suspended until further notice.

**Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Aidigong Maternal & Child Health Limited**  
**Wong Wing Cheung**  
*Company Secretary*

Hong Kong, 18 March 2025

*As at the date of this announcement, the Board comprises Mr. Huang Wenhua, Mr. Lin Jiang, Mr. Li Runping and Ms. Meng Lijia as executive Directors; Mr. Lee Kar Lung as a non-executive Director; and Mr. Shan Guoxin, Mr. Choi Wai Hong Clifford and Mr. Wang Bin as independent non-executive Directors.*